NTLA Stock Overview
A genome editing company, focuses on the development of curative therapeutics.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Intellia Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.99 |
52 Week High | US$34.87 |
52 Week Low | US$14.70 |
Beta | 1.76 |
11 Month Change | -28.62% |
3 Month Change | -42.81% |
1 Year Change | -40.16% |
33 Year Change | -88.95% |
5 Year Change | 17.20% |
Change since IPO | -32.17% |
Recent News & Updates
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Recent updates
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Shareholder Returns
NTLA | US Biotechs | US Market | |
---|---|---|---|
7D | -28.9% | -0.04% | -0.4% |
1Y | -40.2% | 28.6% | 39.5% |
Return vs Industry: NTLA underperformed the US Biotechs industry which returned 28.6% over the past year.
Return vs Market: NTLA underperformed the US Market which returned 39.5% over the past year.
Price Volatility
NTLA volatility | |
---|---|
NTLA Average Weekly Movement | 9.4% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTLA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NTLA's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 526 | John Leonard | www.intelliatx.com |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
Intellia Therapeutics, Inc. Fundamentals Summary
NTLA fundamental statistics | |
---|---|
Market cap | US$1.66b |
Earnings (TTM) | -US$508.80m |
Revenue (TTM) | US$45.97m |
33.1x
P/S Ratio-3.0x
P/E RatioIs NTLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NTLA income statement (TTM) | |
---|---|
Revenue | US$45.97m |
Cost of Revenue | US$448.73m |
Gross Profit | -US$402.76m |
Other Expenses | US$106.03m |
Earnings | -US$508.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -5.01 |
Gross Margin | -876.20% |
Net Profit Margin | -1,106.87% |
Debt/Equity Ratio | 0% |
How did NTLA perform over the long term?
See historical performance and comparison